Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. Show more

Location: 65 Hayden Ave Ste 3000N, Massachusetts, 02421-7994, US | Website: www.concertpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$8.37

Open

$8.37

Volume

N/A

Day Range

$8.37 - $8.37

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

3.77%

Institutional Own.

77.05%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date